Suppr超能文献

肥胖与癌症治疗结果:解读复杂的证据。

Obesity and Cancer Treatment Outcomes: Interpreting the Complex Evidence.

机构信息

Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.

Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK.

出版信息

Clin Oncol (R Coll Radiol). 2020 Sep;32(9):591-608. doi: 10.1016/j.clon.2020.05.004. Epub 2020 Jun 25.

Abstract

A wealth of epidemiological evidence, combined with plausible biological mechanisms, present a convincing argument for a causal relationship between excess adiposity, commonly approximated as body mass index (BMI, kg/m), and incident cancer risk. Beyond this relationship, there are a number of challenges posed in the context of interpreting whether being overweight (BMI 25.0-29.9 kg/m) or obese (BMI ≥ 30.0 kg/m) adversely influences disease progression, cancer mortality and survival. Elevated BMI (≥ 25.0 kg/m) may influence treatment selection of, for example, the approach to surgery; the choice of chemotherapy dosing; the inclusion of patients into randomised clinical trials. Furthermore, the technical challenges posed by an elevated BMI may adversely affect surgical outcomes, for example, morbidity (increasing the risk of surgical site infections), reduced lymph node harvest (and subsequent risk of under-staging and under-treatment) and increased risk of margin positivity. Suboptimal chemotherapy dosing, associated with capping chemotherapy in obese patients as an attempt to avoid excess toxicity, might be a driver of poor prognostic outcomes. By contrast, the efficacy of immune checkpoint inhibition may be enhanced in patients who are obese, although in turn, this observation might be due to reverse causality. So, a central research question is whether being overweight or obese adversely affects outcomes either directly through effects of cancer biology or whether adverse outcomes are mediated through indirect pathways. A further dimension to this complex relationship is the obesity paradox, a phenomenon where being overweight or obese is associated with improved survival where the reverse is expected. In this overview, we describe a framework for evaluating methodological problems such as selection bias, confounding and reverse causality, which may contribute to spurious interpretations. Future studies will need to focus on prospective studies with well-considered methodology in order to improve the interpretation of causality.

摘要

大量的流行病学证据,加上合理的生物学机制,为肥胖症与癌症风险之间存在因果关系提供了令人信服的证据。除了这种关系之外,在解释超重(BMI 25.0-29.9 kg/m)或肥胖(BMI≥30.0 kg/m)是否会对疾病进展、癌症死亡率和生存率产生不利影响时,还存在一些挑战。升高的 BMI(≥25.0 kg/m)可能会影响治疗选择,例如手术方法的选择、化疗剂量的选择、将患者纳入随机临床试验的选择。此外,升高的 BMI 带来的技术挑战可能会对手术结果产生不利影响,例如发病率(增加手术部位感染的风险)、减少淋巴结采集(以及随后分期不足和治疗不足的风险增加)和切缘阳性率增加。由于试图避免过度毒性,超重肥胖患者的化疗剂量受限,这可能是预后不良的原因之一。相比之下,肥胖患者的免疫检查点抑制剂疗效可能增强,尽管反过来,这种观察结果可能是由于反向因果关系。因此,一个核心研究问题是超重或肥胖是否通过癌症生物学的直接影响对结果产生不利影响,或者不良结果是否通过间接途径介导。这种复杂关系的另一个维度是肥胖悖论,即超重或肥胖与改善的生存相关,而这与预期的情况相反。在这篇综述中,我们描述了一种评估方法学问题的框架,例如选择偏倚、混杂和反向因果关系,这些问题可能导致错误的解释。未来的研究需要关注具有良好考虑的方法学的前瞻性研究,以提高因果关系的解释。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验